Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer
- 26 September 2002
- journal article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 81 (2), 87-92
- https://doi.org/10.1002/jso.10137
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5-FluorouracilJapanese Journal of Cancer Research, 2000
- Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I–II NSCLC (non-small cell lung cancer): a randomized clinical trial1European Journal of Cardio-Thoracic Surgery, 1999
- Relationship between Protein Levels and Gene Expression of Dihydropyrimidine Dehydrogenase in Human Tumor Cells during Growth in Culture and in Nude MiceJapanese Journal of Cancer Research, 1998
- Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.Journal of Clinical Oncology, 1997
- A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study)European Journal of Surgical Oncology, 1995
- A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracilEuropean Journal Of Cancer, 1994
- Preliminary Evidence that Incorporation of 5-Fluorouracil into RNA Correlates with Antitumor ResponseCancer Investigation, 1992
- Surgical Treatment of Lung CancerChest, 1991
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Thymidylate synthetase: Mechanism of inhibition by 5-fluoro-2′-deoxyuridylateBiochemical and Biophysical Research Communications, 1972